Neoadjuvant therapy to improve resectability of advanced thyroid cancer: A real‐world experience
- 15 March 2024
- journal article
- research article
- Published by Wiley in Head & Neck
- Vol. 46 (10) , 2496-2507
Abstract
Background: Experience with targeted neoadjuvant treatment for locoregionally advanced thyroid cancer is nascent.Methods: Multicenter retrospective case series examining targeted neoadjuvant treatment for locoregionally advanced thyroid cancer. The primary outcome was change in surgical morbidity as measured by two metrics developed for use in clinical trials to characterize surgical complexity and morbidity. Secondary outcomes included percentage of patients proceeding to surgery and percentage receiving an R0/R1 resection.Results: Seventeen patients with varied molecular alterations, pathologies, and treatment regimens were included. Mean surgical complexity scores decreased between time points for baseline and postneoadjuvant treatment, postneoadjuvant treatment and surgery, and between baseline and surgery. Eleven patients (64.7%) underwent surgical resection, with 10 (58.8%) receiving an R0/R1 resection.Conclusions: Neoadjuvant treatment of advanced thyroid cancer improves resectability and decreases the morbidity of required surgical procedures. However, treatment is not uniformly effective.Keywords
This publication has 24 references indexed in Scilit:
- Successful combination of selpercatinib and radioiodine after pretherapeutic dose estimation in RET-altered thyroid carcinomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2022
- American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatmentHead & Neck, 2022
- The Efficacy and Safety of Anlotinib in Neoadjuvant Treatment of Locally Advanced Thyroid Cancer: A Single-Arm Phase II Clinical TrialThyroid®, 2021
- Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in
BRAF
V600E
-Mutated Anaplastic Thyroid CarcinomaThyroid®, 2019
- Poorly Differentiated Carcinoma of the Thyroid Gland: Current Status and Future ProspectsThyroid®, 2019
- Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancerSeminars in Oncology, 2019
- Neoadjuvant and adjuvant therapy for gastrointestinal stromal tumorsAnnals of Gastroenterological Surgery, 2018
- Aerodigestive Fistula Formation as a Rare Side Effect of Antiangiogenic Tyrosine Kinase Inhibitor Therapy for Thyroid CancerThyroid®, 2014
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Locally invasive papillary thyroid carcinoma: 1940–1990Head & Neck, 1994